Bone Biologics Co. (NASDAQ:BBLG) Sees Large Growth in Short Interest

Bone Biologics Co. (NASDAQ:BBLG) saw a significant increase in short interest in December. As of December 31st, there was short interest totalling 55,100 shares, an increase of 9.8% from the December 15th total of 50,200 shares. Currently, 10.3% of the company’s stock are short sold. Based on an average daily volume of 224,100 shares, the short-interest ratio is presently 0.2 days.

Bone Biologics Stock Performance

Shares of Bone Biologics stock traded up $0.02 during trading on Friday, reaching $0.98. The stock had a trading volume of 26,414 shares, compared to its average volume of 197,204. The stock has a fifty day moving average price of $1.11 and a two-hundred day moving average price of $1.43. Bone Biologics has a 52 week low of $0.80 and a 52 week high of $4.74.

Bone Biologics Company Profile

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.